Azienda Sanitaria Locale Della Provincia Di Lecce
- Address
- Via Antonio Miglietta 5, 73100 Lecce, Italy
Azienda Sanitaria Locale Della Provincia Di Lecce
The Azienda Sanitaria Locale Della Provincia Di Lecce is a comprehensive healthcare institution actively engaged in diverse clinical research initiatives spanning oncology, hematology, infectious disease prevention, and mental health. The center demonstrates particular strength in advanced cancer therapeutics and precision medicine approaches, with emphasis on biomarker-driven treatment strategies and innovative radiation therapy techniques.
- Oncology research focusing on metastatic colorectal cancer, prostate cancer imaging and treatment optimization, and multiple myeloma combination therapies
- Hematological malignancies including chronic lymphocytic leukemia with novel targeted therapy combinations
- Preventive medicine through pneumococcal vaccine studies in pediatric populations
- Neuropsychiatric research evaluating adjunctive therapies for major depressive disorder
The facility specializes in liquid biopsy technology for molecular profiling in colorectal cancer and advanced diagnostic imaging including PET imaging with 64CuCl2 for prostate cancer recurrence detection. Research efforts incorporate stereotactic body radiation therapy (SBRT) protocols and comprehensive investigations of autologous stem cell transplantation combined with novel proteasome inhibitors and immunomodulatory agents in hematologic malignancies. The center's commitment to precision oncology is evidenced through trials examining RAS/BRAF mutation status in guiding targeted therapy selection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Della Provincia Di Lecce
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Study of Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy | Amgen Inc. | Phase III | Not Recruiting | Apr 2025 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone Acetate | 1 | Unknown | 2025-04-28 | 2025-04-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.